Table 5.
HRs for the risk of total and specific cancer except diabetics with a duration of < 6 months
| HR (95% CI) |
||||||
|---|---|---|---|---|---|---|
| Total |
Male |
Female |
||||
| Model 1a | Model 2b | Model 1a | Model 2b | Model 1a | Model 2b | |
| Total | 1.24 (1.23–1.25)c | 1.16 (1.15–1.16)c | 1.28 (1.27–1.29)c | 1.18 (1.17–1.19)c | 1.20 (1.18–1.21)c | 1.13 (1.11–1.14)c |
| Oropharyngeal | 1.03 (1.00–1.07) | 0.93 (0.90–1.00) | 1.10 (1.05–1.16)c | 1.00 (0.95–1.05) | 0.99 (0.94–1.03) | 0.88 (0.85–0.93)d |
| Esophageal | 0.99 (0.92–1.06) | 0.94 (0.87–1.01) | 1.04 (0.96–1.12) | 0.99 (0.91–1.08) | 0.80 (0.66–0.96)d | 0.73 (0.61–0.89)d |
| Stomach | 1.11 (1.09. 1.13)c | 1.08 (1.06–1.11)c | 1.11 (1.08–1.13)c | 1.08 (1.06–1.11)c | 1.13 (1.09–1.17)c | 1.09 (1.05–1.13)c |
| Colorectal | 1.23 (1.21–1.26)c | 1.16 (1.14–1.18)c | 1.24 (1.21–1.27)c | 1.17 (1.14–1.20)c | 1.23 (1.20–1.27)c | 1.16 (1.12–1.19)c |
| Liver | 1.62 (1.60–1.65)c | 1.37 (1.34–1.39)c | 1.71 (1.68–1.75)c | 1.41 (1.39–1.44)c | 1.45 (1.41–1.49)c | 1.28 (1.24–1.32)c |
| Pancreatic | 1.89 (1.84–1.94)c | 1.76 (1.72–1.81)c | 1.96 (1.89–2.03)c | 1.82 (1.75–1.89)c | 1.81 (1.74–1.89)c | 1.69 (1.63–1.77)c |
| Laryngeal | 1.19 (1.09–1.30)c | 1.13 (1.03–1.23)c | 1. 23 (1.12–1.34)c | 1.16 (1.06–1.27)c | 0.99 (0.76–1.30) | 0.91 (0.69–1.19) |
| Lung | 1.10 (1.08–1.13)c | 1.06 (1.04–1.08)c | 1.12 (1.09–1.15)c | 1.09 (1.06–1.12)c | 1.08 (1.04–1.12)c | 1.01 (0.97–1.05) |
| Kidney | 1.37 (1.30–1.44)c | 1.17 (1.12–1.23)c | 1.38 (1.29–1.46)c | 1.19 (1.12–1.26)c | 1.36 (1.26–1.47)c | 1.15 (1.06–1.25)c |
| Bladder | 1.33 (1.27–1.38)c | 1.23 (1.18–1.29)c | 1. 35 (1.29–1.42)c | 1.26 (1.20–1.33)c | 1.30 (1.21–1.40)c | 1.19 (1.10–1.28)c |
| Leukemia | 1.24 (1.13–1.36)c | 1.18 (1.07–1.29)c | 1.19 (1.05–1.35)c | 1.14 (1.00–1.29) | 1.32 (1.14–1.52)c | 1.24 (1.07–1.43)c |
| Thyroid | 1.19 (1.15–1.22)c | 1.12 (1.08–1.15)c | 1.39 (1.31–1.48)c | 1.29 (1.22–1.37)c | 1.13 (1.09–1.17)c | 1.07 (1.03–1.11)c |
| Prostate | 1.21 (1.19–1.23)c | 1.09 (1.07–1.12)c | 1. 21 (1.19–1.23)c | 1.09 (1.07–1.12)c | - | - |
| Breast | 1.05 (1.00–1.09) | 1.03 (0.99–1.08) | - | - | 1.05 (1.00–1.09) | 1.03 (0.99–1.08) |
| Cervical | 1.01 (0.95–1.08) | 0.98 (0.92–1.05) | - | - | 1.01 (0.95–1.08) | 0.98 (0.92–1.05) |
| Endometrial | 1.35 (1.22–1.49)c | 1.29 (1.16–1.43)c | - | - | 1.35 (1.22–1.49)c | 1.29 (1.16–1.43)c |
| Ovary | 1.01 (0.95–1.08) | 0.99 (0.93–1.06) | - | - | 1.01 (0.95–1.08) | 0.99 (0.93–1.06) |
HR, hazard ratio; CI, confidence interval.
a
Model 1 were adjusted for age and sex.
b
Model 2 were adjusted for age, sex, income, place, hypertension, hyperlipidemia, chronic liver disease, ischemic heart disease, and chronic kidney disease.
a
Significantly increased compared to non-diabetes group (p < 0.05).
b
Significantly decreased compared to non-diabetes group (p < 0.05).